18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine patient care. This product is indicated for use in Positive Emission Tomography (PET) in adults and children.
It is used in the diagnosis of various neurological disorders (such as Parkinson's disease), but also in the imaging of specific neuroendocrine tumors.

Neurology

PET with fluorodopa (18F) is indicated to demonstrate a loss of functional dopaminergic nerve endings in the striatum. Defects in dopamine housings are associated with various neurological disorders such as Parkinson's disease. It is therefore used to distinguish essential tremor from parkinsonistic syndromes related to degenerative disorders of the nigrostriatal system (Parkinson's disease, multiple system atrophy and progressive supranuclear palsy).

Oncology

Studies on imaging research show that PET with fluorodopa (18F) allows for a functional approach of pathologies, organs or tissues looking for an increase in intracellular transport and decarboxylation of the amino acid dihydroxyphenylalanine.

Interested in 18F-FDOPA? Contact us to discuss the possibilities.


18F-FDOPA now available

Other news

RTM receives marketing authorisation for Fludeoxyglucose (18F)

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

Read more

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Read more

First Patient Dosed with TLX250-CDx in Italy for ccRCC

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.